On May 18, 2022 Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies for cancer, reported that company management will participate in two upcoming investor conferences in May and June (Press release, Adicet Bio, MAY 18, 2022, View Source [SID1234614830]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of the events are as follows:
H.C. Wainwright Global Investment Conference, May 23-26, 2022
An on-demand presentation will be available beginning Tuesday, May 24th, 2022, at 7:00 A.M. ET.
Jefferies Healthcare Conference, June 8-10, 2022
Chen Schor, President & CEO, will present on Friday, June 10, 2022 at 8:30 A.M. ET.
The live audio webcast of the presentations can be accessed on the Investors section of Adicet Bio’s website at View Source An archived replay will be available for 30 days following the presentation.